Astellas Pharma (OTCMKTS:ALPMY) Issues Quarterly Earnings Results

Astellas Pharma (OTCMKTS:ALPMY) posted its quarterly earnings data on Thursday. The company reported $0.11 earnings per share (EPS) for the quarter, reports. The company had revenue of $2.79 billion during the quarter. Astellas Pharma had a return on equity of 5.85% and a net margin of 1.20%.

Astellas Pharma Price Performance

OTCMKTS:ALPMY opened at $9.55 on Friday. The firm has a market capitalization of $17.28 billion, a price-to-earnings ratio of 27.26, a P/E/G ratio of 1.65 and a beta of 0.32. Astellas Pharma has a 52-week low of $9.15 and a 52-week high of $16.91. The stock has a fifty day moving average of $10.53 and a 200 day moving average of $11.45. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.71 and a current ratio of 0.91.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.